Transcatheter Heart Valve Program Doctors | NYU Langone Health
Find a doctor at the Transcatheter Heart Valve Program at NYU Langone.
Transcatheter Heart Valve Program—Long Island | NYU Langone Health
Doctors at NYU Langone’s Transcatheter Heart Valve Program—Long Island use transcatheter techniques to treat heart valve disease.
Transcatheter Heart Valve Program—Long Island Doctors | NYU Langone Health
Find a doctor at the Transcatheter Heart Valve Program—Long Island at NYU Langone.
Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial
The purpose of the study is to evaluate the safety and efficacy of MedtronicIntrepid™ TMVR System in patients with severe symptomatic mitral regurgitation. Subjects will be randomized on 1:1 basis to either TMVR with the Medtronic Intrepid™ TMVR System or to conventional mitral valve surgery.Subjects ineligible for randomization may be enrolled through a single-arm trial. Subjects enrolled in the single-arm cohort will be assigned to TMVR with the Medtronic Intrepid™ TMVR System.
Transcatheter Procedures for Aortic Valve Disease | NYU Langone Health
At NYU Langone, interventional cardiologists perform nonsurgical transcatheter procedures to repair a damaged aortic valve.
Transcatheter Procedures for Mitral Valve Disease | NYU Langone Health
At NYU Langone, our interventional cardiologists perform transcatheter procedures for mitral valve disease.
Transcatheter Pulmonary Valve Replacement and Catheter Ablation of Ventricular Tachycardia in Tetralogy of Fallot
Patients with TOF that are referred for transcatheter PVR may harbor undiagnosed substrates for sustained monomorphic or polymorphic VT irrespective of their baseline SCD risk. We hypothesize that the combination of VT circuit elimination and favorable reverse remodeling following PVR may operate synergistically to reduce the risk for sustained MVT and SCD for patients with TOF, avoiding the need for alternative therapies. The present study aims to evaluate risk reduction for patients with TOF undergoing transcatheter PVR by performing electrophysiological studies with catheter ablation of demonstrated potential VT substrates prior to transcatheter PVR.
Transcranial Direct Current Stimulation (tDCS) for the Management of Multiple Sclerosis Related Fatigue
This is a pragmatic clinical trial that aims to determine the effect of tDCS on symptomatic fatigue and can directly inform care providers. Our innovative remotely supervised protocol will facilitate study enrollment and study of the cumulative treatment effects. The protocol outlines a randomized, blinded, sham-controlled study design to determine the effect of tDCS on MS participants to reduce feelings of fatigue. n=120 participants with MS and clinically-significant fatigue (as defined by a score of >36 on the Fatigue Severity Scale) will be recruited to participate in either an active or sham treatment condition.
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression R33
~60 subjects with MDD will undergo MRI scanning during t-PBM (administered with an irradiance of 291.7 mW/cm2 for 333s) before and after a randomized, double-blinded, controlled 16-session course of treatment with t-PBM or sham. t-PBM will be administered via NeuroThera’s LightForce® EXPi Deep Tissue Laser TherapyTM System, Transcranial PhotoBioModulation-1000 (tPBM-2.0).
Transcranial Photobiomodulation for Alzheimer's Disease
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham. Subjects will then complete 24 t-PBM/sham treatments, ~6 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).